| Population-based cohorts | Disease cohorts |
---|---|---|
Number of cohorts, n | 20 | 3 |
Number of subjects, n | 75,367 | 4982 |
Men, n (%) | 38,350 (50.9%) | 3766 (75.6%) |
Age at baseline, years | ||
 Median (Q1, Q3) | 50.0 (41.0, 59.0) | 63.0 (54.0, 69.0) |
 Proportion ≥ 65 years | 13.1% | 42.6% |
Daily smokers, n (%) | 24,077 (31.9%) | 892 (17.9%) |
Diabetes, n (%) | 3286 (4.4%) | 930 (18.7%) |
Hypertension, n (%) | 30,811 (40.9%) | 3514 (70.5%) |
Body mass index (kg/m2), mean (SD) | 26.9 (4.6) | 27.6 (4.1) |
Total cholesterol (mmol/L)* | 5.7 (5.0, 6.5) | 4.9 (4.1, 5.7) |
CRP (mg/L)* | 1.3 (0.6, 2.9) | 1.5 (0.4, 5.1) |
Nt-proBNP (pg/mL)* | 45.9 (24.2, 86.3) | 308.0 (116.0, 803.0) |
Troponin I (ng/L)* | 2.3 (1.4, 3.7) | 10.4 (4.6, 29.7) |
eGFR (mL/min/1.73m2)* | ||
 CKD-EPIcrea | 97.6 (85.9, 107.6) | 82.7 (68.7, 94.6) |
 CKD-EPIcysC | 92.5 (76.4, 111.5) | 91.1 (69.1, 116.2) |
CKD stage 3+, n (%) | ||
 CKD-EPIcrea | 2450 (3.3%) | 691 (13.9%) |
 CKD-EPIcysC | 5562 (7.4%) | 719 (14.4%) |
Endpoints (n, incidence rate per 1000 person years (95% CI)) | ||
 Cardiovascular disease | 6850, 8.2 (95% CI 8.0–8.4) | 371, 21.2 (95% CI 19.2–23.5) |
 Cardiovascular mortality | 3796, 4.2 (95% CI 4.1–4.3) | 132, 6.9 (95% CI 5.8–8.2) |
 Total mortality | 9840, 10.9 (95% CI 10.6–11.1) | 343, 17.9 (95% CI 16.1–19.9) |